Lung Cancer News

In this edition, blood test for lung cancer patients who may benefit from further immunotherapy, invasive procedures following lung cancer screenings and more.

Use of subjective minimizing terminology, such as “safe” and “tolerable,” when discussing treatment-related toxicities occurs frequently at oncology and hematology conferences, according to a study published in Journal of Cancer Policy.

Invasive procedures aimed at clearing up imaging abnormalities found on lung cancer screening scans occurred infrequently, according to results published in CHEST.

Circulating tumor DNA analyses can be used as an early marker of immunotherapy response, according to data published in Nature Medicine.

Patients who underwent cancer surgery had an increased risk for venous thromboembolism for up to 1 year after the procedure, results from a retrospective study published in JAMA Network Open showed.

Next-generation technologies and diagnostic tests offer the promise of improved cancer care, but they also present challenges related to ensuring widespread access to these innovations.

As the broader health care field strives to identify and address health care disparities, a commentary published in The Lancet Oncology underscored the importance of eliminating ableism from cancer care.

The proportion of individuals with newly diagnosed cancer who lacked insurance in the U.S. declined significantly from 2010 to 2019, according to data published in Health Affairs Scholar.

Through the power of technology, interventional pulmonology has grown to become a major subspecialty that aids in early diagnosis and treatment of severe lung diseases, such as lung cancer.

Cancer research and advocacy funding disproportionately skewed toward certain subtypes, leaving many cancers with high mortality rates and those affecting Black patients underfunded, study results in JCO Oncology Practice showed.